▶ 調査レポート

世界の若年性黄斑変性症(シュタルガルト病)治療市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界の若年性黄斑変性症(シュタルガルト病)治療市場規模・現状・予測(2021年-2027年) / Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2021-2027 / QYR2104Z3306資料のイメージです。• レポートコード:QYR2104Z3306
• 出版社/出版日:QYResearch / 2021年4月15日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、93ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User/Five User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License(同一法人内共有可)¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査資料では、若年性黄斑変性症(シュタルガルト病)治療のグローバル市場(2016年~2027年)について調べ、市場動向、主要企業の市場シェア、種類別市場規模(幹細胞治療、遺伝子治療、その他)、用途別市場規模(病院、眼科クリニック、その他)、主要地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、関連企業情報などを掲載しています。
・市場概要
・若年性黄斑変性症(シュタルガルト病)治療の市場動向
・企業の競争状況、市場シェア
・若年性黄斑変性症(シュタルガルト病)治療の種類別市場規模(幹細胞治療、遺伝子治療、その他)
・若年性黄斑変性症(シュタルガルト病)治療の用途別市場規模(病院、眼科クリニック、その他)
・若年性黄斑変性症(シュタルガルト病)治療の北米市場規模2016-2027(アメリカ、カナダ)
・若年性黄斑変性症(シュタルガルト病)治療のヨーロッパ市場規模2016-2027(ドイツ、フランス、イギリス等)
・若年性黄斑変性症(シュタルガルト病)治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・若年性黄斑変性症(シュタルガルト病)治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・若年性黄斑変性症(シュタルガルト病)治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Sanofi、Bayer、Roche、Pfizer、Allergan、Gilead Sciences、Kubota Pharmaceutical、Alkeus Pharmaceuticals、Astellas Pharma、Ferrer Corporate)
・結論

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.
Asia Pacific is expected to be the fastest growing market owing to the availability of skilled professional such as ophthalmologist, and eye surgeons. Additionally, improving healthcare infrastructure in developing countries like India is further fuelling the growth of juvenile macular degeneration market. China and India contribute to the growth of the market.

Market Analysis and Insights: Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
The global Juvenile Macular Degeneration (Stargardt Disease) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market.

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Scope and Market Size
Juvenile Macular Degeneration (Stargardt Disease) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Stem Cell Therapy
Gene Therapy
Others

Segment by Application
Hospitals
Eye Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sanofi
Bayer
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Stem Cell Therapy
1.2.3 Gene Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Eye Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Perspective (2016-2027)
2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Growth Trends by Regions
2.2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Industry Dynamic
2.3.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Trends
2.3.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Drivers
2.3.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Challenges
2.3.4 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Revenue
3.1.1 Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Revenue (2016-2021)
3.1.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue
3.4 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio
3.4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in 2020
3.5 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players Head office and Area Served
3.6 Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Solution and Service
3.7 Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Juvenile Macular Degeneration (Stargardt Disease) Treatment Breakdown Data by Type
4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Type (2022-2027)

5 Juvenile Macular Degeneration (Stargardt Disease) Treatment Breakdown Data by Application
5.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2016-2027)
6.2 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
6.2.1 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021)
6.2.2 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027)
6.2.3 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2027)
6.3 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application
6.3.1 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021)
6.3.2 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027)
6.3.3 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2027)
6.4 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country
6.4.1 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021)
6.4.2 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2016-2027)
7.2 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
7.2.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2027)
7.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application
7.3.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2027)
7.4 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country
7.4.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
8.2.1 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application
8.3.1 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Region
8.4.1 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2016-2027)
9.2 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
9.2.1 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2027)
9.3 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application
9.3.1 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2027)
9.4 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country
9.4.1 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
10.2.1 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application
10.3.1 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country
10.4.1 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.1.4 Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.2.4 Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.2.5 Bayer Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.3.4 Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.4.4 Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Allergan
11.5.1 Allergan Company Details
11.5.2 Allergan Business Overview
11.5.3 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.5.4 Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.5.5 Allergan Recent Development
11.6 Gilead Sciences
11.6.1 Gilead Sciences Company Details
11.6.2 Gilead Sciences Business Overview
11.6.3 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.6.4 Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.6.5 Gilead Sciences Recent Development
11.7 Kubota Pharmaceutical
11.7.1 Kubota Pharmaceutical Company Details
11.7.2 Kubota Pharmaceutical Business Overview
11.7.3 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.7.4 Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.7.5 Kubota Pharmaceutical Recent Development
11.8 Alkeus Pharmaceuticals
11.8.1 Alkeus Pharmaceuticals Company Details
11.8.2 Alkeus Pharmaceuticals Business Overview
11.8.3 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.8.4 Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.8.5 Alkeus Pharmaceuticals Recent Development
11.9 Astellas Pharma
11.9.1 Astellas Pharma Company Details
11.9.2 Astellas Pharma Business Overview
11.9.3 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.9.4 Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.9.5 Astellas Pharma Recent Development
11.10 Ferrer Corporate
11.10.1 Ferrer Corporate Company Details
11.10.2 Ferrer Corporate Business Overview
11.10.3 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
11.10.4 Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
11.10.5 Ferrer Corporate Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Stem Cell Therapy
Table 3. Key Players of Gene Therapy
Table 4. Key Players of Others
Table 5. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2016-2021)
Table 9. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2022-2027)
Table 11. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Trends
Table 12. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Drivers
Table 13. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Challenges
Table 14. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Restraints
Table 15. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Players (2016-2021)
Table 17. Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment as of 2020)
Table 18. Ranking of Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Solution and Service
Table 22. Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Sanofi Company Details
Table 63. Sanofi Business Overview
Table 64. Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 65. Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 66. Sanofi Recent Development
Table 67. Bayer Company Details
Table 68. Bayer Business Overview
Table 69. Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 70. Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 71. Bayer Recent Development
Table 72. Roche Company Details
Table 73. Roche Business Overview
Table 74. Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 75. Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 76. Roche Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 80. Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Allergan Company Details
Table 83. Allergan Business Overview
Table 84. Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 85. Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 86. Allergan Recent Development
Table 87. Gilead Sciences Company Details
Table 88. Gilead Sciences Business Overview
Table 89. Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 90. Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 91. Gilead Sciences Recent Development
Table 92. Kubota Pharmaceutical Company Details
Table 93. Kubota Pharmaceutical Business Overview
Table 94. Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 95. Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 96. Kubota Pharmaceutical Recent Development
Table 97. Alkeus Pharmaceuticals Company Details
Table 98. Alkeus Pharmaceuticals Business Overview
Table 99. Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 100. Alkeus Pharmaceuticals Recent Development
Table 101. Astellas Pharma Company Details
Table 102. Astellas Pharma Business Overview
Table 103. Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 104. Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 105. Astellas Pharma Recent Development
Table 106. Ferrer Corporate Company Details
Table 107. Ferrer Corporate Business Overview
Table 108. Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Product
Table 109. Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021) & (US$ Million)
Table 110. Ferrer Corporate Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Stem Cell Therapy Features
Figure 3. Gene Therapy Features
Figure 4. Others Features
Figure 5. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Eye Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Juvenile Macular Degeneration (Stargardt Disease) Treatment Report Years Considered
Figure 10. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2022-2027)
Figure 14. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Players in 2020
Figure 15. Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in 2020
Figure 17. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2016-2027)
Figure 21. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2016-2027)
Figure 22. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Country (2016-2027)
Figure 23. United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2016-2027)
Figure 27. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2016-2027)
Figure 28. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Country (2016-2027)
Figure 29. Germany Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Region (2016-2027)
Figure 39. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Sanofi Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 59. Bayer Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 60. Roche Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 62. Allergan Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 63. Gilead Sciences Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 64. Kubota Pharmaceutical Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 65. Alkeus Pharmaceuticals Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 66. Astellas Pharma Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 67. Ferrer Corporate Revenue Growth Rate in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed